Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cassava Sciences (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, has announced it will hold a conference call and webcast on Thursday, November 7th, 2024, at 8:30 a.m. Eastern Time to report its third quarter 2024 results. The audio webcast will be accessible through the company's website and will remain available for replay for 90 days following the event.
Details
News Market Reaction – SAVA
The recorded move for SAVA in the trading session of this news was -0.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call and webcast to begin at 8:30 AM ET
AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.
| Event details: | |
| Date: | Thursday, November 7th |
| Time: | 8:30 a.m. Eastern Time |
| Audio Webcast: | https://www.CassavaSciences.com/company-presentations |
| Or | |
| Audio Webcast: | https://edge.media-server.com/mmc/p/tzb9j3sy |
A replay of the audio webcast will also be available on the “Company Presentations” page of the Cassava Sciences website for 90 days following the webcast.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.
Simufilam is Cassava Sciences’ small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain. Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Investors
Sandya van der Weid
svonderweid@lifesciadvisors.com
Media
Sitrick And Company
Mike_Sitrick@Sitrick.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.